Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

HSBC upgraded Moderna (MRNA) to Hold from Reduce with a $58 price target Don't Miss our Black Friday Offers:Discover the latest stocks ...

HSBC analyst Yifeng Liu upgraded Moderna (MRNA) to Buy from Hold with a price target of $58, down from $82. The recent share price weakness ...

“ [Trump’s plans] will come at the expense of potentially larger budget deficits, potentially larger debt and there is also ...

The chip company has grown into one of Wall Street’s most influential, with a total market value of nearly $3.5 trillion, ...

U.S. stocks are ticking higher Monday as Wall Street recovers some of last week's sharp slide. The S&P 500 was up 0.5% in ...

Investing.com -- Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the ...

Moderna’s ( NASDAQ: MRNA) steep fall on Friday after President-elect Donald Trump selected vaccine critic Robert F. Kennedy Jr. to head the U.S. Department of Health and Human Services makes a good ...

If confirmed as secretary of Health and Human Services, Kennedy would oversee the US Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) and the head of the Centers ...

Mumbai is bracing for a series of dry days in November due to the upcoming Maharashtra Assembly elections. To ensure a peaceful election process, alcohol sales will be restricted on November 18 ...

In October, more than 100 McDonald’s customers were sickened by an E. coli outbreak in the U.S. linked to slivered onions.